As of Jun 27
| -0.26 / -4.28%|
The 8 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 9.00, with a high estimate of 13.00 and a low estimate of 3.00. The median estimate represents a +54.64% increase from the last price of 5.82.
The current consensus among 9 polled investment analysts is to Buy stock in BioCryst Pharmaceuticals Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.